In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
via Google News
The Latest on: Schizophrenia
Nathan Filer on ‘so-called schizophrenia’ and his new book, The Heartland
on June 15, 2019 at 6:00 am
Scene one: A 29-year-old woman named Erica Crompton is about to be apprehended. Her crimes are serious and varied: every newspaper she looks at carries a headline relating to her. She is a suspect in ... […]
Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults
on June 14, 2019 at 1:08 am
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders ... […]
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
on June 13, 2019 at 5:24 pm
Concert Pharmaceuticals, Inc. CNCE announced positive results from two phase I studies on its pipeline candidate, CTP-692 (a novel deuterium-modified form of D-serine), which is being developed as ... […]
FDA Ad Com July 31 for Intra-Cellular's lumateperone in schizophrenia
on June 13, 2019 at 11:09 am
The FDA's Psychopharmacologic Drugs Advisory Committee will meet on Wednesday, July 31, to review and discuss Intra-Cellular Therapies' (NASDAQ:ITCI) marketing application seeking approval for ... […]
The whisper of schizophrenia: Machine learning finds 'sound' words predict psychosis
on June 13, 2019 at 8:08 am
Automated analysis of the two language variables -- more frequent use of words associated with sound and speaking with low semantic density, or vagueness -- can predict whether an at-risk person will ... […]
Man killed by Orange County deputy had history of schizophrenia, bipolar disorder, family told cops
on June 13, 2019 at 2:42 am
Court documents shed light on the metal health history of the man shot and killed by an Orange County sheriff’s deputy on Tuesday. Eddie Humberto Segura, 40, had previously been diagnosed with ... […]
Psychiatric Co-morbidities in ASD: A Focus on Schizophrenia
on June 10, 2019 at 8:52 am
I recently read a great article on spectrum news about psychiatric co-morbidities in adults with autism (ASD) and attention deficit hyperactivity disorder (ADHD). The news article was summarizing a ... […]
Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study
on June 7, 2019 at 7:25 am
Compared with the general population, people with schizophrenia are both twice as likely to have a diagnosis of cardiovascular disease (CVD), and die as a consequence of CVD 1. The mortality gap ... […]
Neuroscientists use novel technology-based tools to predict schizophrenia
on June 6, 2019 at 11:11 pm
Schizophrenia, a psychiatric disorder that affects about 1% of the population,is a leading cause of functional disability in the United States. Typically diagnosis has hinged on the display of visible ... […]
via Bing News